for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hikma Pharmaceuticals Plc

HIK.L

Latest Trade

2,608.00GBp

Change

-24.00(-0.91%)

Volume

1,930,132

Today's Range

2,608.00

 - 

2,670.00

52 Week Range

1,596.00

 - 

2,768.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
2,632.00
Open
2,621.00
Volume
1,930,132
3M AVG Volume
10.44
Today's High
2,670.00
Today's Low
2,608.00
52 Week High
2,768.00
52 Week Low
1,596.00
Shares Out (MIL)
230.50
Market Cap (MIL)
6,066.67
Forward P/E
20.73
Dividend (Yield %)
1.39

Next Event

Full Year 2020 Hikma Pharmaceuticals PLC Earnings Release

Latest Developments

More

Hikma Pharmaceuticals Says Pat Butler To Become Chair Of Nomination And Governance Committee

Hikma Pharmaceutical Says Increasing FY Guidance For Generics Revenue between $720 Mln To $740 Mln

Hikma And Arecor Agree To Develop And Commercialise Ready-To-Administer Medicine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Industry

Biotechnology & Drugs

Contact Info

1 New Burlington Place

W1S 2HR

United Kingdom

+44.20.73992760

https://www.hikma.com/

Executive Leadership

Said Samih Darwazah

Executive Chairman of the Board

Sigurdur Olafsson

Chief Executive Officer, Executive Director

Mazen Samih Talib Darwazah

Executive Vice Chairman of the Board, President of MENA

Khalid Nabilsi

Chief Financial Officer, Executive Director

Brian Hoffman

President, US Generics Division

Key Stats

2.23 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.9K

2018

2.1K

2019

2.2K

2020(E)

2.3K
EPS (USD)

2017

1.050

2018

1.370

2019

1.500

2020(E)

1.698
Price To Earnings (TTM)
16.65
Price To Sales (TTM)
3.53
Price To Book (MRQ)
4.29
Price To Cash Flow (TTM)
12.74
Total Debt To Equity (MRQ)
49.05
LT Debt To Equity (MRQ)
41.75
Return on Investment (TTM)
19.92
Return on Equity (TTM)
13.57

Latest News

Latest News

Hikma making Gilead's COVID-19 drug remdesivir to increase supply

Britain's Hikma Pharmaceuticals said on Friday it has started manufacturing Gilead's antiviral drug remdesivir under contract in Portugal, as the U.S. company outsources to increase availability of the COVID-19 treatment.

Hikma shares jump after improved sales outlook, COVID-19 drug deal

Hikma Pharmaceuticals raised the sales outlook for its two main divisions on Friday after first-half profit topped the London-listed company's expectations, while also announcing a deal to manufacture coronavirus treatment remdesivir.

UK's Hikma starts manufacturing COVID-19 treatment remdesivir for Gilead

Hikma Pharmaceuticals has started manufacturing remdesivir, an approved treatment for COVID-19 from U.S.-based Gilead, for an undisclosed amount at its facility in Portugal, the British company's chief executive officer said.

Hikma raises annual sales outlook for top two units; profit gains on critical drug demand

Hikma Pharmaceuticals Plc revised its annual sales outlook for two of its biggest divisions on Friday and reported higher first-half profit, as hospitals and distributors stocked up on critical medicines during the COVID-19 pandemic.

BRIEF-Hikma Pharmaceuticals Says Jochen Gann Has Resigned His Directorship Of Co

* HIKMA - JOCHEN GANN HAS RESIGNED HIS DIRECTORSHIP OF HIKMA WITH IMMEDIATE EFFECT

South Africa's Aspen could supply 10 million dexamethasone pills in COVID-19 crisis

South African pharmaceutical major Aspen could provide 10 million dexamethasone tablets within a month, Chief Executive Stephen Saad said on Tuesday after the World Health Organisation cautioned about the drug's supply.

Hikma's major investor to exit nearly 1 billion pound stake in drugmaker

Boehringer Ingelheim, a major shareholder in Hikma Pharmaceuticals <HIK.L>, is exiting the London-listed drugmaker by selling most of its nearly one billion pound stake to institutional investors and the rest back to the company, Hikma said on Monday.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Germany's pharma firm Boehringer to offload stake in drugmaker Hikma

Hikma Pharmaceuticals said on Monday investor Boehringer Ingelheim would sell up to 28 million shares in the London-listed drugmaker, or shares worth about 700 million pounds ($871.43 million), according to a bookrunner for the deal.

BRIEF-Boehringer Ingelheim Intends To Sell Up To About 28 Mln Shares In Hikma

* J.P. MORGAN SEC PLC HIKMA PHARMACEUTICAL - PROPOSED PLACING IN HIKMA PHARMACEUTICALS PLC

BRIEF-Sun Pharma, Hikma Sign Exclusive Licensing Deal For Ilumya For MENA Region

* SUN PHARMA AND HIKMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR ILUMYA FOR MIDDLE EAST & NORTH AFRICA REGIONS

BRIEF-Premier Partners With Hikma Pharmaceuticals To Supply Amiodarone And Sterile Water To Healthcare Providers

* PREMIER INC - PARTNERED WITH HIKMA PHARMACEUTICALS TO SUPPLY AMIODARONE AND STERILE WATER TO HEALTHCARE PROVIDERS Source text for Eikon: Further company coverage:

BRIEF-Hikma Pharmaceutical U.S. Subsidiary Receives FDA Approval For Generic Vascepa

* SUBSIDIARY HIKMA PHARMACEUTICALS USA RECEIVED APPROVAL FROM U.S. FDA FOR ITS ICOSAPENT ETHYL CAPSULES, 1 GM, GENERIC EQUIVALENT TO VASCEPA Source text for Eikon: Further company coverage:

BRIEF-Hikma Launches Propofol Injectable Emulsion, USP, In Response To COVID-19 Shortage

* HIKMA RESPONDS TO COVID-19 SHORTAGE WITH LAUNCH OF PROPOFOL INJECTABLE EMULSION, USP

BRIEF-Hikma Pharmaceutical Maintains 2020 Revenue Outlook

* HIKMA - PROACTIVELY MANAGING OUR INVENTORY AND STOCK LEVELS AND WORKING CLOSELY WITH OUR SUPPLIER NETWORKS

Hikma maintains revenue forecast as pandemic drives demand for some drugs

Hikma Pharmaceuticals <HIK.L> stuck with its full-year revenue forecast for its generic drug business on Thursday, encouraged by high demand for some of its medicines during the COVID-19 pandemic.

BRIEF-Hikma Receives Favourable Ruling In Generic Vascepa

* HIKMA PHARMACEUTICAL - HIKMA'S FAVOURABLE RULING IN GENERIC VASCEPA®

BRIEF-Hikma Pharma Extends Voluntary Nationwide Recall Of Ketorolac Tromethamine Injections Due To Potential Small Particulate Presence

* HIKMA PHARMACEUTICALS USA INC. EXTENDS VOLUNTARY NATIONWIDE RECALL OF KETOROLAC TROMETHAMINE INJECTION, USP 30MG/ML, 1ML FILL/2ML VIALS DUE TO POTENTIAL PRESENCE OF SMALL PARTICULATES

Hikma sees 2020 sales growth after profit beats view on newer drugs

Hikma Pharmaceuticals <HIK.L> on Thursday forecast sales growth this year after it surpassed analysts' expectations for annual operating profit and revenue in 2019, boosted by higher demand for its injectable treatments and newly launched drugs.

BRIEF-India's Glenmark Pharma & UK's Hikma Enter Exclusive Licensing Agreement For Nasal Spray In U.S.

* SAYS CO, HIKMA ENTER EXCLUSIVE LICENSING AGREEMENT FOR COMMERCIALIZING RYALTRIS™ SEASONAL ALLERGIC RHINITIS NASAL SPRAY IN US

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up